SunBio,Inc. (067370) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of SunBio,Inc. stock KRW 5,043, price KRW 4,980, upside +1.3%, quality 58 out of 100. Rating: fairly valued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 4,945 KRW – 34,160 KRW · fair‑value band 1,885 KRW – 6,304 KRW · the 4,980 KRW price screens below the 5,043 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow SunBio in your weekly email
Every Wednesday you see whether SunBio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage.
Show moreShow less
The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives.
The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.
Stock analysis
SunBio,Inc. (067370) currently trades at 4,980 KRW, while our model-based Fair Value estimate is 5,043 KRW, so the stock looks roughly fairly valued today (gap 1.3%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 10,651 KRW per share, and 11 of the 25 models we run sit above the 4,980 KRW price.
Bear case: the Dividend Discount group reads lowest at 907.87 KRW, and 14 of the 25 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 1,885 KRW (bear) to 6,304 KRW (bull), the price of 4,980 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SunBio,Inc. reported revenue of 13.7B KRW in FY2025 versus 7.4B KRW in FY2022, a compound +22.6%/yr. Reported net income was 2.8B KRW in FY2025, compounding +47.6%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap 62.3B KRW (≈ $46.1M) Micro · P/E ratio 43.1 · P/S ratio 8.80 · EPS (TTM) 114.42 KRW · Dividend yield 1.3% · Net margin 20.4% · Return on equity 35.4% · Return on assets (EBIT) 4.7% (4-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 1%, 067370 screens richer than that median.
Fair Value models
Bear1,885 KRWFair Value 5,043 KRWBull6,304 KRW
Price 4,980 KRW · Upside +1.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (98.12 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+57.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.1%
Dividend (yield on the price)1.3%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 37%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+57.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +54.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Top 25%
Fair Value upside+1.3% · Top 25%
Profitability
Return on equity (12 months)35.4% · Top 25%
Return on assets4.6% · Top 25%
Net margin (12 months)64.2% · Top 25%
Operating margin (12 months)16.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Dividend yield (12 months)1.3% · Above median
Balance sheet
Debt / equity0.35× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SunBio,Inc. Fair Value". https://www.fairvalue-calculator.com/stock/067370
Frequently asked questions
Is SunBio,Inc. (067370) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 5,043 KRW versus a price of 4,980 KRW, about +1% upside (fairly valued).
What is the fair value of 067370?
Our model-based fair value for SunBio,Inc. is 5,043 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 4,980 KRW.
What is the quality score of 067370?
SunBio,Inc. has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SunBio,Inc. (067370)?
Our model-based price target is the fair value of 5,043 KRW (as of Nov 3, 2026) from 25 valuation models. Cautious scenario 1,885 KRW, optimistic scenario 6,304 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the SunBio,Inc. stock forecast for 2026?
Our models put fair value at 5,043 KRW, about +1% upside versus a price of 4,980 KRW (fairly valued). Cautious scenario 1,885 KRW, optimistic scenario 6,304 KRW. The calculation is refreshed regularly with new filings.
Does SunBio,Inc. pay a dividend?
SunBio,Inc. currently shows a dividend yield of 1.33% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of SunBio,Inc. (067370)?
SunBio,Inc. has a dividend yield of 1.3%.
What growth is priced into SunBio,Inc. (067370)?
For today's price to be fair in a discounted-cash-flow model, SunBio,Inc. would have to grow free cash flow by +57.4 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +22.6 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 067370 use?
Our models discount SunBio,Inc. at 12.0 %: a base by market capitalisation (micro), damped by beta 0.65, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SunBio,Inc. that is +57.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has SunBio,Inc. (067370) delivered so far?
Over the past 3 years revenue at SunBio,Inc. grew +22.6 % a year. The price currently implies free-cash-flow growth of +57.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SunBio,Inc. (067370) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into SunBio,Inc. (+57.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SunBio,Inc. (067370)?
The free-cash-flow yield on the price is 0.95 %: that much free cash flow SunBio,Inc. produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SunBio,Inc. (067370)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SunBio,Inc. it is 5,043 KRW per share (as of Nov 3, 2026), against a price of 4,980 KRW. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is SunBio,Inc. stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 067370 trades below its calculated fair value: price 4,980 KRW, fair value 5,043 KRW, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 067370?
No. The price is what the market pays today (4,980 KRW); the fair value is what the company's own numbers justify (5,043 KRW). For SunBio,Inc. the two are 63.43 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SunBio,Inc. worth?
The market values SunBio,Inc. at about 62.3B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 4,980 KRW; our models calculate a fair value of 5,043 KRW per share.
What do the bullish and bearish scenarios say about 067370?
Our models span a range for SunBio,Inc.: cautious scenario 1,885 KRW, base 5,043 KRW, optimistic 6,304 KRW per share (as of Nov 3, 2026, price 4,980 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 067370?
SunBio,Inc. trades at a price-to-earnings ratio of 43.1 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 5,043 KRW is built from several models across several years. Other multiples: P/B 2.2, P/S 28.7.
How solid is the balance sheet of SunBio,Inc. (067370)?
Balance-sheet figures for SunBio,Inc. (as of Nov 3, 2026): return on equity 35.4%, debt of 0.35 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 067370 from its 52-week high?
SunBio,Inc. trades at 4,980 KRW, about 40% below its 52-week high of 8,290 KRW and 1% above the low of 4,945 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 5,043 KRW is for.
Which stocks are comparable to SunBio,Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SunBio,Inc. stock attractive at the current price?
The data as of Nov 3, 2026: price 4,980 KRW, calculated fair value 5,043 KRW (+1%), Quality Score 58/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 067370 calculated?
We run SunBio,Inc. through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5,043 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SunBio,Inc. currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SunBio,Inc. (067370)?
The closing price on Nov 6, 2026 was 4,980 KRW. Our model-based fair value is 5,043 KRW, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SunBio,Inc. right now?
The model range is unusually wide (1,885 KRW to 6,304 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of SunBio,Inc.
How large is the market capitalisation of SunBio,Inc. (067370)?
The market capitalisation of SunBio,Inc. is 62.3B KRW (≈ $46.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SunBio,Inc. (067370)?
The price-to-sales ratio of SunBio,Inc. is 8.80 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SunBio,Inc. (067370)?
Earnings per share at SunBio,Inc. are 114.42 KRW (price ÷ EPS = P/E 43.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SunBio,Inc. (067370)?
The dividend yield of SunBio,Inc. is 1.3% (payout 58.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SunBio,Inc. (067370)?
The net margin of SunBio,Inc. is 20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SunBio,Inc. (067370)?
The return on equity (ROE) of SunBio,Inc. is 35.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SunBio,Inc. (067370)?
On an EBIT basis the return on assets of SunBio,Inc. is 4.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SunBio,Inc. (067370)?
The operating margin of SunBio,Inc. is 16.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net debt does SunBio,Inc. (067370) carry?
The net debt of SunBio,Inc. is 25.7B KRW (fiscal year 2025, ≈ 44.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SunBio,Inc. in the live analysis
One click puts SunBio,Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026